Federal data shows opioid shipments ballooned as crisis grew

CLEVELAND — Newly released federal data shows how drugmakers and distributors increased shipments of opioid painkillers across the U.S. as the nation's addiction crisis accelerated from 2006 to 2012.

The data, released this week by a federal court in Ohio as part of a far-reaching opioids case, shows that companies distributed 8.4 billion hydrocodone and oxycodone pills to commercial pharmacies in 2006 and 12.6 billion in 2012. That's an increase of over 50%.

Over that seven-year period, 76 billion pills were distributed in all, according to an analysis by The Washington Post, which had sued along with another outlet, HD Media, to obtain the data. During the same timeframe, prescription opioids contributed to more than 100,000 deaths in the U.S., according to the U.S. Centers for Disease Control and Prevention.

The shipments increased even after one of the companies, Purdue Pharma, was leveled with a $635 million federal fine in 2007 for falsely claiming its drug, OxyContin, was not as addictive as earlier opioids.

While OxyContin is the best-known prescription opioid, the Post analysis shows that Purdue accounted for just 3% of pills sold during that time. Three makers of generic drugs accounted for nearly 90% of the sales.

The data tracks a dozen different opioids, including oxycodone and hydrocodone, according to the Post. They account for most of the pill shipments to pharmacies.

The distribution data, maintained by the U.S. Drug Enforcement Agency, is a key element of lawsuits filed by more than 2,000 state, local and tribal governments seeking to hold drug companies accountable for the crisis.

Drug distribution companies told The Post that the federal data would not exist without their providing accurate reports to the DEA. One company, AmerisourceBergen, said the data "offers a very misleading picture."

Cleveland-based U.S. District Judge Dan Polster, who is overseeing most of the cases, ruled Monday that the information covering shipments from 2006 to 2012 could be made public. He said in a ruling that there is "clearly no basis" for shielding older data.

His order came a month after a federal appeals court in Cincinnati vacated Polster's July 2018 decision that local and state governments, which had been granted access to the data, should not make it public.

A three-judge panel for the 6th U.S. Court of Appeals said Polster went too far in blocking the release of data that government attorneys argued could compromise DEA investigations. Polster asked attorneys from all sides Monday to suggest how DEA data collected for 2013 and 2014 should be protected.

The Washington Post and HD Media, which owns newspapers in West Virginia, went to court for access and were the first media outlets to receive the data. By Tuesday, it had not been made available to the public or other news organizations that had requested it, including The Associated Press.

In a statement, a group of plaintiff attorneys applauded Polster's decision.

"The data provides statistical insights that help pinpoint the origins and spread of the opioid epidemic — an epidemic that thousands of communities across the country argue was both sparked and inflamed by opioid manufacturers, distributors and pharmacies," the statement said.

The first scheduled trial before Polster is set for October in lawsuits filed by Ohio's Summit and Cuyahoga counties, areas that have been hit particularly hard by the ongoing opioid crisis. It is considered a bellwether trial that could force the defendants to reach a global settlement for all of the lawsuits.

A trial in an opioid suit brought by Johnson & Johnson by Oklahoma in state court there wrapped up this week. A judge will rule on that case. Purdue and Teva Pharmaceutical Industries Ltd. were named in that suit but settled before the trial.

___

Associated Press writer Geoff Mulvihill in Cherry Hill, New Jersey, contributed to this report.

You may also interested in

Valeant, attempting to normalize operations, names new CFO

Aug 22, 2016

Valeant Pharmaceuticals is replacing Robert Rosiello as chief financial officer as the embattled pharmaceutical company attempts to normalize operations amid a host of ongoing investigations and class action suits

Delphi, Mobileye join forces on autonomous car platform

Aug 23, 2016

Auto parts and electronics company Delphi Automotive is joining with Israeli software maker Mobileye to develoDelphi and Mobileye plan to build a complete autonomous driving platformp the building blocks for a fully autonomous car in about two years

How EpiPen's maker raised prices, and hackles, so much

Aug 23, 2016

Sky-high price hikes for an emergency allergy medicine are making drugmaker Mylan the latest target for patients and politicians infuriated by soaring drug costs

People also read these

Officials: Zika won't hurt South Florida tourism in long run

Aug 20, 2016

The discovery of Zika-carrying mosquitoes in South Florida certainly isn't ideal for tourism, but local officials and business leaders are confident the long-term impact on the tourism industry will be minor

Delphi, Mobileye join forces on autonomous car platform

Aug 23, 2016

Auto parts and electronics company Delphi Automotive is joining with Israeli software maker Mobileye to develoDelphi and Mobileye plan to build a complete autonomous driving platformp the building blocks for a fully autonomous car in about two years

Yosemite, and President Obama, head into virtual reality

Aug 25, 2016

In a new project with National Geographic, Barack Obama becomes the first sitting U.S. president to project himself into virtual reality _ in this case, a 360-degree representation of Yosemite National Park

Emporium Post fulfils the need to know all things about consumers and how businesses can take this opportunity to reach their own customers.

Contact us: sales@emporiumpost.com

Join our mailing list now!